Market Newsdesk

ENGLEWOOD, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) — Gevo, Inc. (NASDAQ: GEVO) announced today that it will host a conference call on February 24, 2022 at 4:30 p.m. EST (2:30 p.m. MST) to report its financial results for the fourth quarter ended December 31, 2021 and provide an update on recent corporate highlights.

To participate in the conference call, please dial (833) 729-4776 (inside the U.S.) or (830) 213-7701 and reference the access code 3465026#.

A replay of the call will be available two hours after the conference call ends on February 24, 2022. To access the replay, please visit https://edge.media-server.com/mmc/p/38zwqbqa

The archived webcast will be available in the Investor Relations section of Gevo’s website at www.gevo.com.

About Gevo

Gevo’s mission is to transform renewable energy and carbon into energy-dense liquid hydrocarbons. These liquid hydrocarbons can be used for drop-in transportation fuels such as gasoline, jet fuel, and diesel fuel, that when burned have potential to yield net-zero greenhouse gas emissions when measured across the full lifecycle of the products. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials, and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo’s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo’s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo’s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.

Gevo believes that Argonne National Laboratory GREET model is the best available standard of scientific based measurement for life cycle inventory or LCI.

Learn more at Gevo’s website: www.gevo.com

Investor and Media Contact

Heather Manuel, VP of Investor Relations and Corporate Communications
[email protected]
+1 720-418-0085

SAN ANTONIO, Texas, Jan. 19, 2022 (GLOBE NEWSWIRE) — Usio, Inc. (Nasdaq: USIO), an integrated electronic payment solutions provider, today announced that the City of Oakland Department of Transportation (California) has chosen the Company’s proprietary prepaid card technology as the payment solution for its groundbreaking Universal Basic Mobility Pilot.

Louis Hoch, President and Chief Executive Officer of Usio, said, “As the acknowledged leader in electronic payments solutions for guaranteed income programs, we are pleased to have developed innovative technology that will help the Oakland DOT make access to their transportation network more affordable to those in need. Like the numerous other guaranteed income programs we support around the country for governmental entities both large and small, we developed a customized payment solution for Oakland DOT that provides a contemporary payment technology that is responsive to both their needs as well as those of their constituents. I want to thank the Oakland DOT for their confidence in Usio, and we look forward to supporting this very worthy program.”

“Usio provided us with a product that aids our efforts to increase public transit, bikeshare, and e-scooter in Oakland trips using grant funds,” said Quinn Wallace, Parking & Mobility Division, City of Oakland, Department of Transportation. “As our work progresses, Usio continues to be highly responsive and understanding of both our project needs and regulatory context as a public entity, including our privacy policies.”

Under this pilot program, citizens living or working in East Oakland can apply to receive up to $300 that can be used only for transit and shared mobility on a prepaid debit card. Up to 500 participants have been randomly selected from qualified applicants. More on this and similar programs across the United States can be found at: https://www.bloomberg.com/news/articles/2021-11-11/u-s-cities-test-effects-of-universal-basic-mobility?sref=81ZfsQPj

Houston Frost, Senior Vice President-Prepaid Services, added, “For many people, the lack of access to affordable transportation is a barrier to workforce participation. The Oakland Department of Transportation’s Universal Basic Mobility Pilot innovative program attempts to solve that problem. This is another example of how our proprietary prepaid technology simplifies and helps facilitate the implementation of various forms of guaranteed income programs. Usio’s solutions allow for the efficient disbursement of funds, the ability to control how those funds can be used and provides the managers of the program with actionable insight. As guaranteed income programs gain increasing acceptance across the country, Usio will be there with customized solutions that can help these organizations better serve their constituents.”

About Usio, Inc.

Usio, Inc. (Nasdaq: USIO), a leading FinTech integrated payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, crypto exchanges and card issuers. The Company operates credit, debit/prepaid, and ACH payment processing platforms to deliver convenient, world-class payment solutions and services to its clients. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the prepaid sector. Usio is headquartered in San Antonio, Texas, and has offices in Austin, Texas and Franklin, Tennessee, just outside of Nashville.
Websites: www.usio.com, www.payfacinabox.com, www.akimbocard.com and www.usiooutput.com. Find us on Facebook^® and Twitter

FORWARD-LOOKING STATEMENTS DISCLAIMER


Except for the historical information contained herein, the matters discussed in this release include forward-looking statements which are covered by safe harbors. Those statements include, but may not be limited to, all statements regarding management’s intent, belief, and expectations, such as statements concerning our future and our operating and growth strategy. These forward-looking statements are identified by the use of words such as “believe,” “intend,” “look forward,” “anticipate,” “continue,” and “expect” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks related to an economic downturn as a result of the COVID-19 pandemic, the realization of opportunities from the IMS acquisition, the management of the Company’s growth, the loss of key resellers, the relationships with the Automated Clearinghouse network, bank sponsors, third-party card processing providers and merchants, the security of our software, hardware and information, the volatility of the stock price, the need to obtain additional financing, risks associated with new legislation, and compliance with complex federal, state and local laws and regulations, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its annual report on Form 10-K for the fiscal year ended December 31, 2020. One or more of these factors have affected, and in the future, could affect the Company’s businesses and financial results in the future and could cause actual results to differ materially from plans and projections. The Company believes that the assumptions underlying the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that the objectives and plans will be achieved. All forward-looking statements made in this release are based on information presently available to management. The Company assumes no obligation to update any forward-looking statements, except as required by law.

Contact:

Joe Hassett, Investor Relations
[email protected]
484-686-6600

More than 20 million households & two million businesses now have access to game changing Internet

Make sure you get all the benefits of Verizon’s 5G Ultra Wideband network for your home, phone & business by following these easy steps

NEW YORK, Jan. 19, 2022 (GLOBE NEWSWIRE) — Now that America’s most reliable network¹ is going Ultra, it’s time to get the most out of Verizon’s 5G Ultra Wideband network,² which will be available to 100 million more people this month in over 1,700 cities around the nation. More than 20 million households now have access to game-changing home wireless broadband, and more than 2 million businesses are covered with 5G Business Internet service.

Our new 5G Ultra Wideband Unlimited plans – 5G Get More, 5G Play More and 5G Do More – give you all the benefits of 5G Ultra Wideband and much more offered for the same price as today’s plans. Our 5G Home Internet plans, 5G Home and 5G Home Plus, change the game with a plug and play self set up, guaranteed pricing, no annual contracts, no extra fees, no data overages or equipment charges – all at an incredible value. 5G Ultra Wideband is also available for your business with 5G Business Unlimited mobile plans – Business Unlimited Plus and Business Unlimited Pro – and multiple plans for fixed-wireless 5G Business Internet from Verizon Business.

Here is a checklist to make sure you’re ready to enjoy all the benefits of 5G Ultra Wideband for your phone, home and business.

For your phone:

• Get one of our latest 5G phones. To experience the benefits of 5G Ultra Wideband, you’ll need one of our latest 5G phones with the latest software update in your settings. There’s never been a better time to upgrade or switch. We’re offering great deals on our best 5G smartphones in store, on the My Verizon App or online at verizon.com/5g/phones/. Shop devices for your business at verizon.com/5gdevices.
• Sign up for our 5G Ultra Wideband Unlimited plans. To get the most out of 5G Ultra Wideband, you’ll want to be on one of our newest plans. To sign up for our new 5G Ultra Wideband Unlimited plans – 5G Get More, 5G Play More and 5G Do More– visit a store, use the My Verizon app or go to verizon.com/plans/unlimited. New plans for business include the Business Unlimited Plus Data Device and the Business Unlimited Pro Data Device. Shop plans for your business at verizon.com/business/plans.
• Look for the indicator. Once you’ve got your 5G phone and your new plan, look for the “5G UW” indicator on the top right corner of your phone. You’re all set!

Internet for your home:

• Plug in your address. Visit verizon.com/5G/home and put in your address. We’ll let you know what service is available in your area.
• Choose your plan. Select the 5G Home Internet plan that best serves your needs. Once you’ve chosen your plan, we’ll send you everything that you need for a simple self-setup. You’ll be up and running in no time. Have your mobile service with Verizon? Get 50 percent off 5G Home when you are on one of our new 5G Ultra Wideband Unlimited plans. You can even get the first month on us.³
• Check back often. If 5G Home has not yet come to you, we’ve got other internet options to fit your needs, like LTE Home Internet and Fios Internet. We’re constantly expanding our networks, so check back often to see what services are available in your neighborhood.

Internet for your business:

• Plug in your address: Visit verizon.com/5gbusinessinternet and plug in your business address. We’ll let you know what service you qualify for.
• Choose your plan. Select the plan that best serves your needs. We’ll take care of the rest either online or with the help of your Verizon business partner.
• Check back often. If 5G Business Internet has not yet come to you, we’ve got other internet options to fit your needs, like LTE Business Internet and Fios Business Internet. We’re constantly expanding our networks, so check back often to see what services are available in your area.

5G Ultra Show

Verizon debuted the “5G Ultra Show” to highlight the transformative power of Verizon 5G Ultra Wideband in everyday life. For a replay and highlights, visit Verizon.com/5G.

¹America’s most-reliable network based on rankings from the RootMetrics® US National
RootScore
® Report 1H 2021. Tested with the best commercially available smartphones on 3 national mobile networks across all available network types combined, excl. C-Band. No
t a specific finding as to 5G networks. Results may vary. Not an endorsement.

²

5G
Ultra Wideband
available in select areas.

³
50% off 5G Home internet: Save 50% off 5G Home Internet when you combine your plan with 5G Do More, 5G Play More or 5G Get More plan. With Auto Pay and paper-free billing req’d. One month promo credit applied via bill credit over 1-2 billing cycles. Subject to VZW Agmts and credit approval.

Verizon Communications Inc. (NYSE, Nasdaq: VZ) was formed on June 30, 2000, and is one of the world’s leading providers of technology and communications services. Headquartered in New York City and with a presence around the world, Verizon generated revenues of $128.3 billion in 2020. The company offers data, video and voice services and solutions on its award-winning networks and platforms, delivering on customers’ demand for mobility, reliable network connectivity, security and control.

VERIZON’S ONLINE MEDIA CENTER: News releases, stories, media contacts and other resources are available at verizon.com/news. News releases are also available through an RSS feed. To subscribe, visit www.verizon.com/about/rss-feeds/.

Media contact:

Andrew Testa
[email protected]
862-324-0275

Alex Lawson
[email protected]
908-635-0271

MELBOURNE, Australia, Jan. 19, 2022 (GLOBE NEWSWIRE) — Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, ‘Company’, ‘GENE’, ‘geneType’), a diversified Genomics and AI driven preventative health business, provides its results for the quarter ended December 31, 2021.

Highlights:

• Solid cash balance of A$13.5 million and increased customer receipts of A$1.8 million further extending runway for growth
• ‘One company two brands’ approach leverages EasyDNA acquisition with launch of the Multi-Test product
• Multi-Test technical validation complete and submitted to NATA¹ and CMS² for final regulatory approval ahead of the commercial release
• Multi-Test to address a burgeoning market determining personal risk of developing a range of serious diseases including:
  • breast cancer
  • colorectal cancer
  • ovarian cancer
  • prostate cancer
  • coronary artery disease
  • type 2 diabetes

• US patent application for novel geneType COVID-19 Risk Test has been accepted and cross validation study completed in independent cohort confirming test performance and utility
• Study of 200,000 participants presented at 2021 San Antonio Breast Cancer Symposium validating the risk model with an expanded panel of 313 Single Nucleotide Polymorphisms (SNPs)

• EasyDNA distribution network provides access to a significant addressable market with 70 websites in 40 countries and further engagement with IBX on the COVID-19 Risk Test
• COVID-19 Risk Test – expanded US patient access with new partnership agreement signed with 1Health and IBX. Cross validation study completed, independent cohort confirms test performance and utility. Emergence of new strains of COVID-19, such as Omicron, highlight the importance and utility of GENE’s COVID-19 Risk Test.

EasyDNA Acquisition and geneType Brand Launch

GENE announced the acquisition of EasyDNA in July 2021 and completed the settlement process in August 2021. The four months since settlement focused on the integration of our people, products and EasyDNA platform to deliver a “One Company-Two Brand” approach for GENE. This will drive a clearer marketing and engagement structure for new and existing products coming to market. Importantly, further integration will continue over the coming quarters as the Company works to further leverage and grow the existing network of 70 websites across 40 countries.

Overall, the Company is in a strong position with a portfolio of high-quality products both in the market and under development and a substantial international platform for the distribution of the Direct-to-Consumer product base via EasyDNA.

As part of the EasyDNA integration, the Company announced the launch of the geneType rebrand in November 2021. The geneType brand is the overarching business and brand, while the EasyDNA brand with its existing network, will represent the consumer facing brands and products and drive increased awareness of GENE’s product portfolio.

Total cash receipts for the quarter from EasyDNA were A$1.8 million in line with acquisition expectations. The Company is focused on further embedding the acquisition with the inclusion of the Multi-Test and expects to see continued solid growth in revenue across all brands and products.

Commercialization and Product Overview

The Company’s strategy to commence commercialization and enhance the product distribution network is well underway. Key avenues for commercialization of launched products currently include the consumer-initiated testing and online sales and marketing platform (CIT) available in Australia and the US. With the recent inclusion of the EasyDNA business the Company intends to leverage this platform to enhance the visibility and awareness of its existing products.

Core products for release include GENE’s geneType for Breast Cancer, geneType for Colorectal Cancer and the COVID-19 Risk Test with the commercial release of the Company’s Multi-Test to cover both Colorectal Cancer and Breast Cancer in addition to Prostate Cancer, Ovarian Cancer, Coronary Artery Disease and Type 2 Diabetes.

GENE now has distribution coverage in Australia and the US and has identified Europe and the UK as further expansion opportunities for the Company. The Company is assessing the European CE certification requirements for its products and will update the market on its progress within these regions as further clarity on timing is obtained. An Asian market entry for relevant products will also be assessed in due course.

Multi-Test Product Commercial Release

In late December 2021, the Company confirmed it is set to release phase one of its Multi-Test, subject to receiving final regulatory approval and confirms that all regulatory submissions to NATA and CMS have been completed. NATA completed their onsite audit of GENE’s Melbourne laboratory on December 15, 2021. The certifying body is preparing their final documentation on the audit in the coming weeks.

The phase one launch is the culmination of 10+ years of research and development and include Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Coronary Artery Disease and Type 2 diabetes. The Company is now focused on finalizing commercial distribution opportunities via our EasyDNA brand and through our existing partner network with IBX, 1 Health and Vitagene.

The direct-to-consumer genetic testing market represents a significant growth opportunity for GENE, the total worldwide market is expected to grow from US$1.2 billion in 2020 to US$2.6 billion³ in 2025, an increase of US$1.4 billion. The growth of the DTC segment is driven by a number of factors including a broader understanding of the growing demand for disease risk analysis.

Of particular relevance to GENE’s Multi-Test development is the emergence of Precision Medicine and its ability to classify individuals into subpopulations that differ in their susceptibility to a particular disease. GENE’s Risk Assessment Tests are an important part of eliminating the traditional “one size fits all” approach, enabling preventive or therapeutic measures to be concentrated on patients who will gain the most benefit, significantly improving patient outcomes and health economics.

COVID-19 Risk Test

In December 2021, the Company announced a new partnership to expand access to the COVID-19 Risk Test in the US through its agreement with IBX and 1health on their ‘Vitagene’ platform directly from https://genetype.com/for-individuals/COVID-19/.

1health is a leading US-based cloud platform service provider for diagnostic test management. 1health has built infrastructure that helps laboratories, such as IBX and their customers, connect patients to testing and care. 1health’s services will be managed in partnership with IBX under our three-year co-exclusive licence agreement previously announced on March 3, 2021.

The Company has continued to expand and develop the geneType COVID-19 Risk Test, having recently completed a cross-validation study on a European data set confirming the test performance metrics. A paper describing the study has now been submitted to a peer-reviewed journal and will be released upon publication. The emergence of the Omicron variant underscores the importance of being able to identify those patients, whether vaccinated or not, who are at greater risk of developing severe disease.

The geneType COVID-19 Risk Test is designed to predict disease severity in people aged 18 and older, using genetic and clinical information providing a risk score that can be used to understand a person’s risk of contracting a serious case of COVID-19. In addition, employers, governments, and other public health entities may use the data to make informed decisions about disease risk, treatment options, and importantly guiding vaccination and booster priorities. According to the Centers for Disease Control and Prevention, as of January 15, 2022, only 74.9% of the US population had received at least one shot of a COVID-19 vaccine, leaving approximately 83 million Americans unvaccinated. The geneType COVID-19 Risk Test could assist these people to better understand their risk of severe disease, while providing those who are vaccinated (approximately 249 million people) with an incentive to obtain a booster if they are at high risk of severe disease.

Research and Publications

Over the quarter, the Company has continued to invest in its product development supporting a self-funded study in collaboration with the Institute of Public Health in St Louis, and continued progress with the Multi-Test slated for release in the coming months.

In December 2021, GENE’s Director of Clinical Affairs, Dr Erika Spaeth presented a poster at the San Antonio Breast Cancer Symposium. In her presentation, Dr Spaeth released new data that demonstrated a next generation version of the Company’s geneType Breast Cancer Test with an expanded panel of 313 SNPs showed improved discrimination and calibration over traditional clinical models. The study included over 200,000 women and highlighted GENE’s commitment to the ongoing development of geneType Breast Cancer Risk Test.

The Company is pleased to report a further peer-reviewed research publication entitled “Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank” Gafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL (2021) was published on PLOS.

The study describes how the addition of a polygenic risk score to a family history model improves the stratification and discriminatory performance of both 10 year and full lifetime risk using a prospective population-based cohort within the UK Biobank.

Current screening guidelines in the UK, USA and Australia focus solely on family history and age for risk prediction, even though the vast majority of the population do not have any family history. The results support the view that a combined polygenic risk score and first-degree family history model could be used to improve risk stratified population screening programs.

Outlook

The Company remains focused on the commercialization opportunities for the Multi-Test, continued leveraging the EasyDNA brand and product suite to grow the revenue base, further investment in R&D to enhance our Multi-Test offering and COVID-19 Risk Test and continuing to remain at the cutting edge of genetic testing and preventative health.

Commenting on the forward outlook, Simon Morriss stated: “We are pleased with the progress made over this quarter and with the integration of the EasyDNA team while continuing to advance our product commercialization pathway opportunities.

Investor Webinar

The Company will provide an investor webinar to discuss the quarterly results. To register please follow the link below.

Date: Friday January 21, 2022
Time: 9:30am AEDT
Registration Link:https://us02web.zoom.us/webinar/register/WN_YLLED0yxRHGiDMX6htX8jg

Investor Relations (AUS)	Investor Relations and Media (US)
Stephanie Ottens	Dave Gentry
Market Eye	1 800 RED CHIP (733 2447)
M: +61 434 405 400	Cell: 407 491 4498
E: [email protected]	E: [email protected]

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GENE offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products geneType for Breast Cancer for non-hereditary breast cancer and geneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.

For more information, please visit www.genetype.com

Forward-Looking Statements

This press release may contain forward-looking statements about the Company’s expectations, beliefs or intentions regarding, among other things, statements regarding the expected use of proceeds. In addition, from time to time, the Company or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by the Company with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the approval of one of the Company’s authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause the Company’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause the Company’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements as detailed in the Company’s filings with the Securities and Exchange Commission and in its periodic filings in Australia and the risks and risk factors included therein. In addition, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its control.  The Company does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

______________________

¹ National Association of Testing Authorities, Australia
² Centers for Medicare & Medicaid Services
³ https://www.technavio.com/report/direct-to-consumer-genetic-testing-market-size-industry-analysis&nowebp

SCHAUMBURG, Ill., Jan. 19, 2022 (GLOBE NEWSWIRE) — Paylocity (NASDAQ: PCTY), a leading provider of cloud-based HR and payroll software solutions, today announces the acquisition of Cloudsnap Inc., a flexible, low-code solution for integrating disparate business applications.

Cloudsnap’s technology enables seamless integration of systems to automate manual data exchange processes, creating a modern user experience. The company’s integration automation platform facilitates development and deployment of API integrations, allowing clients to automate data flows across systems such as HR and financial applications.

Integrating HR tools with third-party systems has historically relied on manual processes or heavily customized integrations, which are difficult and time consuming. This often means that HR teams can’t easily share data across business systems and functions, creating business inefficiencies, data errors, and compliance challenges. Cloudsnap technology will enable Paylocity to deliver modern integrations and seamless data sharing between critical systems more efficiently and effectively, while helping to unify and automate business processes across HR, Finance, Benefits, and other systems.

“Legacy HCM vendors have not designed their systems to support end-to-end processes and data flows across third-party systems, yet HR touches virtually every part of an organization,” said Steve Beauchamp, CEO of Paylocity. “This acquisition will accelerate the speed and flexibility with which organizations can connect data and insights from Paylocity to other mission-critical business applications, so we can continue to provide the most relevant and modern platform for our clients.”

“Data drives businesses, but organizations still struggle with multiple systems that don’t connect to each other, and integration continues to pose major challenges to business agility,” said Matt Bradley, CEO of Cloudsnap. “We’re thrilled to join Paylocity at a time when the HR function is so instrumental for a company’s success.”

Paylocity expects Cloudsnap to have an immaterial impact to third quarter and fiscal 2022 financial results and will update financial guidance in the normal course of business in its second quarter fiscal 2022 earnings release.

About Paylocity:

Paylocity (NASDAQ: PCTY) is a leading provider of cloud-based HR and payroll software solutions headquartered in Schaumburg, IL. Founded in 1997 and publicly traded since 2014, Paylocity offers an intuitive, easy-to-use product suite that helps businesses tackle today’s challenges while moving them toward the promise of tomorrow. Known for its unique culture and consistently recognized as one of the best places to work, Paylocity accompanies its clients on the journey to create great workplaces and help people achieve their best through automation, data-driven insights, and engagement. For more information, visit www.paylocity.com.

About Cloudsnap:

Cloudsnap enables companies to seamlessly integrate disparate business applications. Cloudsnap removes the burden of manual process, allowing companies to automate data flows across business applications, such as ERPs, CRMs, and HCMs. More information at www.cloudsnap.com.

Safe Harbor/Forward Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included herein regarding Paylocity’s future operations, ability to scale its business, future financial position and performance, future revenues, projected costs, prospects, plans, and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “will,” “would,” “seek,” and similar expressions (or the negative of these terms) are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among other things, statements about Paylocity’s acquisition of Cloudsnap, anticipated client benefits, and general business outlook. Paylocity may not actually achieve the expectations disclosed in the forward-looking statements, and you should not place undue reliance on Paylocity’s forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results or events to differ materially from the expectations disclosed in the forward-looking statements, including, but not limited to the possibility that the anticipated synergies of the unified solution may not be achieved after closing; the combined operations may not be successfully integrated in a timely manner, if at all; challenges associated with expanding and evolving a sales organization to effectively address new geographies and products and services; challenges related to cybersecurity threats and evolving cybersecurity regulations; general economic conditions in regions in which Paylocity and Cloudsnap do business, including the ongoing impact of the novel coronavirus disease (“COVID-19”) on the U.S. and global economy, including reductions in interest rates, business disruptions, reductions in employment, and an increase in business failures that have occurred or may occur in the future; and the possibility that Paylocity or Cloudsnap may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Paylocity. In addition, please refer to the other risks and potential factors that could affect Paylocity’s business and financial results identified in Paylocity’s filings with the Securities and Exchange Commission (the “SEC”), including its 10-K filed with the SEC on August 6, 2021. Additional information will also be set forth in Paylocity’s future quarterly reports on Form 10-Q, annual reports on Form 10-K, and other filings that Paylocity makes with the SEC. These forward-looking statements represent Paylocity’s expectations as of the date of this press release. Subsequent events, including events relating to the COVID-19 pandemic and its severity, duration, and ultimate impact, may cause these expectations to change, and Paylocity disclaims any obligations to update or alter these forward-looking statements in the future, whether as a result of new information, future events, or otherwise.

CONTACT:  
Brad Buyce
[email protected]
404-895-3998

January 19, 2021 

• The American Heart Association’s multi-year initiative, supported by Philips, aims to bring forward the latest education and clinical data to increase awareness for providers and patients in the pursuit of guideline-driven CIED care
• Every year in the USA less than 30% of patients with CIED infections are treated properly in accordance with guidelines
  [1,2,3]

Amsterdam, the Netherlands –

Royal Philips
(NYSE: PHG, AEX: PHIA), a global leader in health technology, is supporting the American Heart Association’s multi-year effort to generate awareness among cross-disciplinary specialties and improve survival rates from cardiovascular implantable electronic device (CIED) infections.

With the support of Philips, the American Heart Association’s national CIED infection initiative will work with medical professionals across a variety of specialities to prevent and properly treat infections resulting from cardiovascular implantable electronic devices such as pacemakers, implantable cardioverter-defibrillators and cardiac resynchronization devices.

Each year one million CIEDs are implanted worldwide [4] and one in 20 of these patients will develop a CIED infection [5] within three years. Support of efforts by the American Heart Association follows similar efforts by Philips, like its ‘No Infection Left Behind’ initiative, which aims to advance education for healthcare providers to help accurately diagnose CIED infections and deliver timely care.

Patients diagnosed with CIED infections are often treated with antibiotics, which is not an effective treatment option – 50-100% of patients treated with antibiotics alone will experience an infection relapse [6,7]. Clinical practice guidelines recommend extraction for all patients with a definite CIED infection, including complete device and lead removal. Too often, healthcare professionals lack awareness and experience in CIED infection management, increasing the chance of a missed infection diagnosis and prolonging inappropriate treatment. It is estimated that in the USA more than 7,000 CIED patient lives are at risk each year due to improper treatment. Yet complete CIED extraction is proven safe and effective, especially at an earlier stage of infection, which can reduce mortality rates [8,9] and long-term costs.

“CIED infection is a major public health problem with substantial morbidity and mortality,” said Jonathan Piccini, M.D., M.H.S., Director of Cardiac Electrophysiology section at the Duke Heart Center and the current chair of the American Heart Association Get With The Guidelines®-AFib quality improvement registry. “Despite the tremendous impact of these infections on patients and their loved ones, potential life-saving guideline recommended care is infrequently applied.”

“By supporting the American Heart Association, we have a significant opportunity to improve care for a large group of cardiovascular patients,” said Chris Landon, Senior Vice President and General Manager Image Guided Therapy Devices at Philips. “At Philips, we want to support medical professionals and their efforts to follow guideline-directed care and decrease the complications and negative outcomes that too often follow CIED infections.”

“We are pleased to receive the support of Philips on this important effort to raise awareness for CIED infection care, reduce mortality rates among patients and improve guideline driven care of people living with CIED devices,” said Michele Bolles, Senior Vice President Quality, Outcomes Research & Analytics at the American Heart Association. “We know that patient outcomes improve when guideline-directed care is consistently provided. These efforts amplify the mission of the American Heart Association to help every person have the opportunity for a longer, healthier life.”

Learn more about CIED infection:

• Through Philips ELITE Academy & Deviceinfection.com Philips has made resources available including education materials, data, case studies and Lead Management solutions to help educate providers in CIED infections.
• 
  Overcoming Barriers to Complete and Early Extraction for CIED Infection: A Narrative Review of the Epidemiological, Clinical and Economic Evidence.
  This presentation, recently presented at the AHA Scientific Sessions by Ami Sood, M.D. from Philips, provides an overview of the many barriers patients face in receiving optimal treatments including challenges with infection diagnosis, patient referral to extraction centers and negative misconceptions regarding extraction procedures.
• American Heart Association at heart.org
• If you are a patient seeking to learn more about managing your heart device and finding a lead extractor, visit the Heart Rhythm Society for CIED management

[1] Sohail, M. R., Eby, E. L., Ryan, M. P., Gunnarsson, C., Wright, L. A., & Greenspon, A. J. (2016, Aug). Incidence, Treatment Intensity, and Incremental Annual Expenditures for Patients Experiencing a Cardiac Implantable Electronic Device Infection: Evidence From a Large US Payer Database 1-Year Post Implantation. Circ Arrhythm Electrophysiol, 9(8). https://doi.org/10.1161/circep.116.003929.
[2] Dai, M., Cai, C., Vaibhav, V., Sohail, M. R., Hayes, D. L., Hodge, D. O., Tian, Y., Asirvatham, R., Cochuyt, J. J., Huang, C., Friedman, P. A., & Cha, Y. M. (2019, Sep). Trends of Cardiovascular Implantable Electronic Device Infection in 3 Decades: A Population-Based Study. JACC Clin Electrophysiol, 5(9), 1071-1080. https://doi.org/10.1016/j.jacep.2019.06.016.
[3] Data on File. CIED Infection Treatment Inadequate Adherence to Guidelines.
[4] Greenspon A.J. J Am Coll Cardiol 58:1001–1006.; Kremers MS, Heart Rhythm 2013; 10:e59.
[5] Cantillon D. JACC EP. 2017.
[6] del Rio A, Anguera I, Miro JM, et al. Surgical treatment of pacemaker and defibrillator lead endocarditis: the impact of electrode lead extraction on outcome. Chest 2003;124:1451–9.
[7] Chua, J.D., et al. (2000). Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Annals of Internal Medicine, 133(8): 604-608.
[8] Le, K. Y., et al. (2011, Nov). Impact of timing of device removal on mortality in patients with cardiovascular
implantable electronic device infections. Heart Rhythm, 8(11), 1678-1685. 21.
[9] Greenspon, A. J., et al. (2018, May). Treatment patterns, costs, and mortality among Medicare beneficiaries
with CIED infection. Pacing Clin Electrophysiol, 41(5), 495-503.

For further information, please contact:

Joost Maltha 
Philips Global Press Office 
Tel: +31 6 10 55 8116  
E-mail: [email protected]

Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: [email protected]

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 78,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Physician talks to patient

BURNABY, British Columbia, Jan. 19, 2022 (GLOBE NEWSWIRE) —

Michael Xie, Founder, President and CTO at Fortinet

“We are proud to once again be included in Glassdoor’s Best Places to Work list in Canada. We are committed to a culture of innovation focused on openness and teamwork to enable our employees to learn and build long-term careers in cybersecurity and at Fortinet. We owe this recognition to our employees, they are vital to the growth and success of the company.”

News Summary

Fortinet® (NASDAQ: FTNT), a global leader in broad, integrated, and automated cybersecurity solutions, today announced it has been honored with a Glassdoor Employees’ Choice Award, recognizing the Best Places to Work in Canada in 2022. The program is based entirely on the input of employees who voluntarily provide feedback on their workplace experience and companies on Glassdoor, one of the world’s largest job and recruiting sites.

Winners are ranked based on their overall rating achieved during the past year through Glassdoor’s employee reviews covering career opportunities, compensation and benefits, culture and values, diversity and inclusion, senior management and work-life balance. Fortinet currently has an overall 4.2 rating from 1,400+ reviews. This is the second time Fortinet has been on the list since 2019, moving from number eight to number seven in the Canada-wide list.

View the full list of Glassdoor’s Best Places to Work in Canada for 2022, which features winning employers hiring across a range of industries, including technology, finance, government, telecommunications, travel & tourism and more.

Additional Resources

• Read about how Fortinet is committed to cybersecurity innovation with more than 1500 patents either awarded or pending.
• 
  Watch
  how Fortinet makes possible a digital world you can always trust, and view how the Fortinet Security Fabric platform delivers broad, integrated, and automated protection across an organization’s entire digital infrastructure.
• Read more about how Fortinet customers are securing their organizations.
• Engage in the Fortinet User Community (Fuse). Share ideas and feedback, learn more about our products and technology, and connect with peers.
• Follow Fortinet on Twitter, LinkedIn, Facebook, and Instagram. Subscribe to Fortinet on YouTube.

About Fortinet

Fortinet (NASDAQ: FTNT) makes possible a digital world that we can always trust through its mission to protect people, devices, and data everywhere. This is why the world’s largest enterprises, service providers, and government organizations choose Fortinet to securely accelerate their digital journey. The Fortinet Security Fabric platform delivers broad, integrated, and automated protections across the entire digital attack surface, securing critical devices, data, applications, and connections from the data center to the cloud to the home office. Ranking #1 in the most security appliances shipped worldwide, more than 550,000 customers trust Fortinet to protect their businesses. And the Fortinet NSE Training Institute, an initiative of Fortinet’s Training Advancement Agenda (TAA), provides one of the largest and broadest training programs in the industry to make cyber training and new career opportunities available to everyone. Learn more at https://www.fortinet.com, the Fortinet Blog, or FortiGuard Labs.

FTNT-O

Copyright © 2022 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, FortiGate, FortiGuard, FortiCare, FortiManager, FortiAnalyzer, FortiOS, FortiADC, FortiAP, FortiAppMonitor, FortiASIC, FortiAuthenticator, FortiBridge, FortiCache, FortiCamera, FortiCASB, FortiClient, FortiCloud, FortiConnect, FortiController, FortiConverter, FortiDB, FortiDDoS, FortiExplorer, FortiExtender, FortiFone, FortiCarrier, FortiHypervisor, FortiInsight, FortiIsolator, FortiMail, FortiMonitor, FortiNAC, FortiPlanner, FortiPortal, FortiPresence , FortiProxy, FortiRecorder, FortiSandbox, FortiSIEM, FortiSwitch, FortiTester, FortiToken, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLCOS and FortiWLM.

Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments. This news release may contain forward-looking statements that involve uncertainties and assumptions, such as statements regarding technology releases among others. Changes of circumstances, product release delays, or other risks as stated in our filings with the Securities and Exchange Commission, located at www.sec.gov, may cause results to differ materially from those expressed or implied in this press release. If the uncertainties materialize or the assumptions prove incorrect, results may differ materially from those expressed or implied by such forward-looking statements and assumptions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Fortinet assumes no obligation to update any forward-looking statements, and expressly disclaims any obligation to update these forward-looking statements.

Media Contact:	Investor Contact:	Analyst Contact:
John Welton	Peter Salkowski	Ron Davis
Fortinet, Inc.	Fortinet, Inc.	Fortinet, Inc.
408-235-7700	408-331-4595	415-806-9892
[email protected]	[email protected]	[email protected]

JERSEY CITY, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) — AvePoint (NASDAQ: AVPT), the most advanced SaaS and data management platform provider, today launched Confide, a virtual data room to help businesses manage sensitive data needs, and collaborate with greater confidence. Confide is the only virtual data room fully integrated with Microsoft 365, and hosted on the end-user cloud tenant, providing optimal security and initiation efficiency.

Confide enables businesses to seamlessly work with both internal and external actors, without the concern of data breaches, accidental exposure, and costly mistakes, especially when engaging in highly confidential projects like mergers and acquisitions, financial audits, intellectual property, and executive collaboration. Powered by the same technology behind AvePoint’s IT products, Confide provides the following for business leaders:

• Simple Setup: Instead of tasking IT with building a new secure workspace, which can slow down business-critical decisions, Confide empowers business leaders to build their projects intuitively and safely. Seamless integration with Microsoft 365 not only provides familiar user-experience, but it also reduces the number of SaaS solutions required for work.
• Robust Governance: Business leaders can apply and control granular, project-specific permissions that allow full control and transparency across the sensitive project lifecycle. Additionally, secure, in-line communication and task management ensures all discussions occur, and data exists, within the project, as opposed to in email or external chats.
• Real Time Insights and Intelligence: To manage activity within projects, business leaders have centralized access to analytics that show document viewership, editing status, and permissions.

“The importance of securing all business data has never been clearer than in the past two years, against the backdrop of record volume of data breaches, enterprises continuing to amass business data exponentially into Cloud, and more sensitive activities like M&A occurring across the board,” said Dr. Tianyi Jiang (TJ), CEO and Co-Founder, AvePoint. “By equipping business leaders with the same enterprise-grade security functionality we’ve provided IT for years, we continue our commitment securing digital collaboration, which has grown both in scope and importance.”

Unlike other virtual data rooms, Confide is an application where all uploaded data is securely stored within the organization’s own Office 365 tenant. Additionally, Confide was designed to intentionally restrict IT admin access, and only grant access to the business leaders within the organization who should be privy to such sensitive information. This is different from other forms of private channels that exist within Microsoft Teams, Slack or Google Workspace, for example.

“For highly sensitive projects, business leaders should be the ones to control, build, govern and protect that data,” said John Peluso, Chief Product Officer, AvePoint. “AvePoint has always aimed to improve IT operations, and as a result of empowering business leaders through Confide, we can reduce strain on IT teams and enable them to focus on other priorities.”

As part of its commitment to helping businesses collaborate with confidence, AvePoint also launched Fly, its cloud migration product, as a SaaS solution. Now, in addition to migrating from on-prem to the cloud, or from cloud to cloud as a one-time project, Fly can be used to support migrations due to M&A activity or further digital transformation.

To learn more about Confide, attend the virtual launch event on Thursday, January 20^th at 11am EST, or visit www.confide.me.

About AvePoint
  
Collaborate with confidence. AvePoint provides the most advanced platform for SaaS and data management to optimize SaaS operations and secure collaboration. More than 8 million cloud users rely on our solutions. Our SaaS solutions are also available to managed service providers via more than 100 cloud marketplaces, so they can better support and manage their small and mid-sized business customers. Founded in 2001, AvePoint is a five-time Global Microsoft Partner of the Year and headquartered in Jersey City, New Jersey. For more information, visit https://www.avepoint.com.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 or otherwise, including with respect to AvePoint’s Confide and Fly products and services. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical facts. These forward-looking statements are, by their nature, subject to significant risks and uncertainties and are based on the beliefs of AvePoint’s management as well as assumptions made by and information currently available to AvePoint’s management. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of AvePoint including those set forth in the Risk Factors section of AvePoint ‘s most recent Quarterly Report on Form 10-Q and its registration statement on Form S-1 and related prospectus and prospectus supplements filed with the SEC. Copies of these and other documents filed by AvePoint from time to time are available on the SEC’s website, www.sec.gov. AvePoint undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Media Contact


Nicole Caci
AvePoint
[email protected]
201-201-8143

Seanergy
Maritime
Announces
Additional
$
5
Million
Buyback
of Convertible Notes

Total Completed Buyback
s
of $
21.6
million
to date

January
19
, 202
2
–
Glyfada
, Greece – Seanergy Maritime Holdings Corp. (the “Company” or “Seanergy”) (NASDAQ: SHIP) announced today an aggregate of $5 million in buyback and partial elimination of the outstanding convertible note (the “Note”), utilizing 50% of its second share repurchase plan (the “Plan”).
As previously announced and following the full completion of the first share repurchase plan, the Board of Directors authorized the additional Plan, under which the Company might repurchase up to an additional $10 million of its common shares, convertible notes or warrants.

The Note carries a 5.5% coupon, has a $1.20 per share conversion price and is held by Jelco Delta Holding Corp. (“Jelco”). Based on the conversion price, the buyback is preventing potential dilution of 4.17 million shares. Seanergy will realise annual interest savings of $275,000 as a result of the deleveraging effect of the prepayment. Moreover, the Company’s cash sweep obligations for 2022 under its outstanding loan and Note with Jelco have been waived.

The Company expects to record a non-cash accounting loss of approximately $1.5 million in the first quarter of 2022, associated with the accounting treatment of the Note. Nonetheless, the prepayment will have a positive impact on the income statement for 2022-24 through the elimination of non-cash charges of an average of $0.5 million per year.

Stamatis Tsantanis, the Company’s Chairman & Chief Executive Officer, stated:

“I am pleased to announce another repurchase of the Company within a very short period of time. These buybacks reflect our strong confidence in the Company and the Capesize market. We firmly believe that both the current levels of our share price and the conversion price of the Notes are lagging far behind the true value of the Company.

“We remain committed to enhancing shareholder value. In this context, we further reduce our financial leverage and diminish the potential dilution from outstanding share-linked instruments, eliminating legacy overhang on our share price. At the same time, our interest expense is expected to further decline following the prepayment, benefiting the daily cash break-even of the fleet.”

About Seanergy Maritime Holdings Corp.

Seanergy Maritime Holdings Corp. is the only pure-play Capesize ship-owner publicly listed in the US. Seanergy provides marine dry bulk transportation services through a modern fleet of Capesize vessels. The Company’s operating fleet consists of 17 Capesize vessels with an average age of 11.7 years and aggregate cargo carrying capacity of approximately 3,011,083 dwt.

The Company is incorporated in the Marshall Islands and has executive offices in Glyfada, Greece. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and its Class B warrants under “SHIPZ”.

Please visit our company website at: www.seanergymaritime.com.

Forward-Looking Statements

This press release contains forward-looking statements (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates” and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company’s operating or financial results; the Company’s liquidity, including its ability to service its indebtedness; competitive factors in the market in which the Company operates; shipping industry trends, including charter rates, vessel values and factors affecting vessel supply and demand; future, pending or recent acquisitions and dispositions, business strategy, areas of possible expansion or contraction, and expected capital spending or operating expenses; risks associated with operations outside the United States; risks associated with the length and severity of the ongoing novel coronavirus (COVID-19) outbreak, including its effects on demand for dry bulk products and the transportation thereof; and other factors listed from time to time in the Company’s filings with the SEC, including its most recent annual report on Form 20-F. The Company’s filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, the Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

For further information please contact:

Seanergy Investor Relations
Tel: +30 213 0181 522
E-mail: [email protected]

Capital Link, Inc.
Paul Lampoutis
230 Park Avenue Suite 1536
New York, NY 10169
Tel: (212) 661-7566
E-mail: [email protected]

Attachment

• 2022-1-19_SHIP additional buyback